Nimotuzumab Enhances the Radiosensitivity of Cancer Cells In Vitro by Inhibiting Radiation-Induced DNA Damage Repair

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Qu, Yuan yuan ^a   Hu, Song liu ^a   Xu, Xiang ying ^a,b   Wang, Rui zhi ^a   Yu, Hong yang ^c   Xu, Jian yu ^a   Chen, Lin ^a   Dong, Guang lu ^c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Water Resources Research Institute of Heilongjiang Province   (China)

^c THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PROTEIN KINASE C;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CELL STRAIN MCF 7; CLONOGENIC ASSAY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MOLECULAR MECHANICS; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; DNA-ACTIVATED PROTEIN KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA RAYS; GENE EXPRESSION REGULATION; HISTONES; HUMANS; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84881575090     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070727     Document Type: Article

References (25)

1. Verheij M, Vens C, van Triest B, (2010) Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective. Drug Resist Updat 13: 29-43.
2. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, et al. (2005) The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11: 795-805.
3. Reade CA, Ganti AK, (2009) EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics 3: 215-24.
4. Chen DJ, Nirodi CS, (2007) The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 13: 6555-60.
5. Zhuang HQ, Sun J, Yuan ZY, Wang J, Zhao LZ, et al. (2009) Radiosensitizing effects of gefitinib at different administration times in vitro. Cancer Sci 100: 1520-25.
6. Boland W, Bebb G, (2010) The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics 4: 289-98.
7. Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, et al. (2011) Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 11: 373-82.
8. Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, et al. (2009) Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 1: 41-8.
9. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, et al. (2008) Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 98: 749-55.
10. Diaz Miqueli A, Rolff J, Lemm M, Fichtner I, Perez R, et al. (2009) Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer 100: 950-58.
11. Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, et al. (2010) Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors overexpressing EGFR. Cancer Biol Ther 10: 673-81.
12. Rodriguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, et al. (2010) Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 9: 343-9.
13. Dittmann K, Mayer C, Rodemann HP, (2005) Inhibition of radiation-induced EGFR nuclear import by C225(Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76: 157-61.
14. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, et al. (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280: 31182-89.
15. Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, et al. (2008) Gefitinib Radiosensitizes Non-Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity. Clin Cancer Res 14: 1266-73.
16. Chinnaiyan P, Huang S, Vallabhaneni G, Sato M, Minna JD, et al. (2005) Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva). Cancer Res 65: 3328-35.
17. Burtness B, Goldwasser MA, Flood W, (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646-54.
18. Bonner JA, Harari PM, Giralt J, (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-78.
19. Blumenschein GR Jr, Paulus R, Curran WJ, Robert F, Fossella F, et al. (2011) Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 29: 2312-8.
20. Jensen AD, Münter MW, Bischoff HG, Haselmann R, Haberkorn U, et al. (2011) Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer 117: 2986-94.
21. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-71.
22. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-705.
23. Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A, (2002) Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 101: 567-75.
24. Toulany M, Kasten-Pisula U, Brammer I, Wang S, Chen J, et al. (2006) Blockage of epidermal growth factor receptor-Phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-ras mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 12: 4119-26.
25. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Löbrich M, et al. (2004) ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 64: 2390-6.